Steve N. Slilaty & Sunshine Biopharma

Steve N. Slilaty: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Rivaroxaban, highlighting its importance for the company's generics market position.

Sunshine Biopharma: Sunshine Biopharma received approval for its generic Rivaroxaban tablets in Canada, expanding its portfolio of anticoagulant drugs and strengthening its position in the generics market.

Steve N. Slilaty: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Anastrozole, highlighting its importance for the company's generics portfolio and commitment to affordable medicines.

Sunshine Biopharma: Sunshine Biopharma received Canadian regulatory approval for its generic Anastrozole tablets, expanding its portfolio in breast cancer therapy and strengthening its position in the generics market. This approval is expected to contribute to its financial growth.

Steve N. Slilaty: Dr. Steve N. Slilaty, CEO of Sunshine Biopharma, authorized the board to consider a reverse stock split.

Sunshine Biopharma: Sunshine Biopharma successfully closed a public offering, raising $6 million in gross proceeds with potential for an additional $12 million from warrant exercises, which will be used for general corporate purposes and working capital. This financing is substantial relative to its market capitalization and addresses its negative free cash flow.